Sitong Wu

Ms. Sitong Wu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Journal of Luminescence
Verified
Journal Article
Closed access
Jiayan LiaoJiayan Liao
Jiayan Liao
LYLiu Yang
Liu Yang
SWSitong Wu
Sitong Wu
ZYZhichao Yang
Zhichao Yang
Jiajia ZhouJiajia Zhou
Jiajia Zhou
MGMing Guan
Ming Guan

4 January 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ACAochiu Chen
Aochiu Chen
RRRebecca N. Re
Rebecca N. Re
TDTony D. Davis
Tony D. Davis
KTKelley Tran
Kelley Tran
YMYuta W. Moriuchi
Yuta W. Moriuchi
MBMichael D. Burkart
Michael D. Burkart

Verified
Journal Article
Open access
PDF file
SWSitong Wu
Sitong Wu
ENEsveidy Isabel Oceguera Nava
Esveidy Isabel Oceguera Nava
DADennis Ashong
Dennis Ashong
GCGuanglin Chen
Guanglin Chen
QCQiao-Hong Chen
Qiao-Hong Chen
The androgen receptor (AR) signaling pathway is the primary driver of prostate cancer initiation and progression, including the development of castration-resistant prostate cancer (CRPC). Because current AR-targeted therapies inevitably encounter drug resistance, novel strategies to suppress AR signaling are urgently needed. Natural products represent a rich and structurally diverse source of bioactive compounds capable of targeting AR at multiple regulatory levels. This review overviews the interactions between natural products and the AR signaling axis through distinct mechanisms, including inhibition of testosterone production and 5α-reductase activity, direct antagonism of AR, and induction of AR degradation. In addition, several compounds disrupt AR nuclear translocation, downregulate AR splice variants, or suppress AR signaling indirectly through epigenetic regulation, microRNA modulation, or interference with co-regulator networks. Preclinical studies provide compelling evidence that these agents can effectively interrupt AR signaling, thereby suppressing prostate cancer growth. However, challenges remain, particularly the limited pharmacokinetic characterization, lack of in vivo validation, and scarcity of clinical studies. Future research should focus on improving bioavailability, exploring synergistic combinations with existing therapies, and advancing well-designed in vivo and clinical investigations. Collectively, these efforts may establish natural products as lead compounds to modulate AR signaling for prostate cancer prevention and treatment.